'Intriguing' data On GSK's ICOS Agonist For Head And Neck Cancer

 
• By Kevin Grogan

As it continues to build a presence in oncology, the company is starting a late-stage trial of GSK3359609 combined with Merck & Co's blockbuster Keytruda on the back of data presented at ESMO.

Blacksmiths
In oncology, GSK is hoping to have more irons in the fire • Source: Shutterstock

More from Immuno-oncology

More from Anticancer